Skip to main content
profile image
Selected Works of Carlo B. Bifulco, M.D.
Article
PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab
OncoImmunology (2017)
  • Gabriele Madonna, Melanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy.
  • Carmen Ballesteros-Merino, Providence Portland Medical Center
  • Zipei Feng, Oregon Health & Science University
  • Zipei Feng, Providence Portland Medical Center
  • Carlo Bifulco, Providence Portland Medical Center
  • Mariaelena Capone, Melanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy.
  • Diana Giannarelli, Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy.
  • Domenico Mallardo, Melanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy.
  • Ester Simeone, Melanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy.
  • Antonio M. Grimaldi, Melanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy.
  • Corrado Caracò, Melanoma and Sarcoma Surgery Unit, Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy.
  • Gerardo Botti, Unit of Pathology, IRCCS, Istituto Nazionale Tumori, Fondazione "G. Pascale", Naples, Italy.
  • Bernard A. Fox, Oregon Health & Science University
  • Bernard A. Fox, Providence Portland Medical Center
  • Paolo A. Ascierto, Melanoma Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy.
Link
Disciplines
Publication Date
November 17, 2017
DOI
10.1080/2162402X.2017.1405206
Citation Information
Gabriele Madonna, Carmen Ballesteros-Merino, Zipei Feng, Zipei Feng, et al.. "PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab" OncoImmunology Vol. 7 Iss. 12 (2017) p. 0 - 0
Available at: http://works.bepress.com/carlo-bifulco/72/